Background: The high prevalence of distant metastatic disease among patients with pancreatic cancer often draws attention away from the local pancreatic tumor. This study aimed to define the complications and hospitalizations from local versus distant disease progression among a retrospective cohort of patients with pancreatic cancer. Methods: Records of 298 cases of pancreatic cancer treated at a single institution from 2004 through 2015 were retrospectively reviewed, and cancer-related symptoms and complications requiring hospitalization were recorded. Hospitalizations related to pancreatic cancer were attributed to either local or distant progression. Cumulative incidence analyses were used to estimate the incidence of hospitalization, and multivariable Fine-Gray regression models were used to identify factors predictive of hospitalizations. Results: The 1-year cumulative incidences of hospitalization due to local versus distant disease progression were 31% and 24%, respectively. Among 509 recorded hospitalizations, leading local etiologies included cholangitis (10%), biliary obstruction (7%), local procedure complication (7%), and gastrointestinal bleeding (7%). On multivariable analysis, significant predictors of hospitalization from local progression included unresectable disease (subdistribution hazard ratio [SDHR], 2.42; P<.01), black race (SDHR, 3.34; P<.01), younger age (SDHR, 1.02 per year; P=.01), tumor in the pancreatic head (SDHR, 2.19; P<.01), and larger tumor size (SDHR, 1.13 per centimeter; P=.02). Most patients who died in the hospital from pancreatic cancer (56%) were admitted for complications of local disease progression. Conclusions: Patients with pancreatic cancer experience significant complications of local tumor progression. Although distant metastatic progression represents a hallmark of pancreatic cancer, future research should also focus on improving local therapies.
Background: The high prevalence of distant metastatic disease among patients with pancreatic cancer often draws attention away from the local pancreatic tumor. This study aimed to define the complications and hospitalizations from local versus distant disease progression among a retrospective cohort of patients with pancreatic cancer. Methods: Records of 298 cases of pancreatic cancer treated at a single institution from 2004 through 2015 were retrospectively reviewed, and cancer-related symptoms and complications requiring hospitalization were recorded. Hospitalizations related to pancreatic cancer were attributed to either local or distant progression. Cumulative incidence analyses were used to estimate the incidence of hospitalization, and multivariable Fine-Gray regression models were used to identify factors predictive of hospitalizations. Results: The 1-year cumulative incidences of hospitalization due to local versus distant disease progression were 31% and 24%, respectively. Among 509 recorded hospitalizations, leading local etiologies included cholangitis (10%), biliary obstruction (7%), local procedure complication (7%), and gastrointestinal bleeding (7%). On multivariable analysis, significant predictors of hospitalization from local progression included unresectable disease (subdistribution hazard ratio [SDHR], 2.42; P<.01), black race (SDHR, 3.34; P<.01), younger age (SDHR, 1.02 per year; P=.01), tumor in the pancreatic head (SDHR, 2.19; P<.01), and larger tumor size (SDHR, 1.13 per centimeter; P=.02). Most patients who died in the hospital from pancreatic cancer (56%) were admitted for complications of local disease progression. Conclusions: Patients with pancreatic cancer experience significant complications of local tumor progression. Although distant metastatic progression represents a hallmark of pancreatic cancer, future research should also focus on improving local therapies.
Authors: Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang Journal: J Gastrointest Oncol Date: 2022-02
Authors: Abhinav V Reddy; Colin S Hill; Shuchi Sehgal; Jin He; Lei Zheng; Joseph M Herman; Jeffrey Meyer; Amol K Narang Journal: J Gastrointest Oncol Date: 2022-06
Authors: Colin S Hill; Lauren Rosati; Hao Wang; Hua-Ling Tsai; Jin He; Amy Hacker-Prietz; Daniel A Laheru; Lei Zheng; Shuchi Sehgal; Vincent Bernard; Dung T Le; Timothy M Pawlik; Matthew J Weiss; Amol K Narang; Joseph M Herman Journal: Pract Radiat Oncol Date: 2022-03-17
Authors: Colin S Hill; Sarah Han-Oh; Zhi Cheng; Ken Kang-Hsin Wang; Jeffrey J Meyer; Joseph M Herman; Amol K Narang Journal: Radiat Oncol Date: 2021-03-19 Impact factor: 3.481
Authors: Colin Hill; Shuchi Sehgal; Wei Fu; Chen Hu; Abhinav Reddy; Elizabeth Thompson; Amy Hacker-Prietz; Dung Le; Ana De Jesus-Acosta; Valerie Lee; Lei Zheng; Daniel A Laheru; William Burns; Matthew Weiss; Christopher Wolfgang; Jin He; Joseph M Herman; Jeffrey Meyer; Amol Narang Journal: Cancer Med Date: 2022-02-10 Impact factor: 4.452
Authors: Shalini Moningi; Xiudong Lei; Penny Fang; Cullen M Taniguchi; Emma B Holliday; Eugene J Koay; Albert C Koong; Ethan B Ludmir; Bruce D Minsky; Prajnan Das; Sharon H Giordano; Grace L Smith Journal: Clin Transl Radiat Oncol Date: 2022-04-19
Authors: William A Hall; Christina Small; Eric Paulson; Eugene J Koay; Christopher Crane; Martijn Intven; Lois A Daamen; Gert J Meijer; Hanne D Heerkens; Michael Bassetti; Stephen A Rosenberg; Katharine Aitken; Sten Myrehaug; Laura A Dawson; Percy Lee; Cihan Gani; Michael David Chuong; Parag J Parikh; Beth A Erickson Journal: Front Oncol Date: 2021-05-11 Impact factor: 5.738
Authors: Abhinav V Reddy; Shuchi Sehgal; Colin S Hill; Lei Zheng; Jin He; Joseph M Herman; Jeffrey Meyer; Amol K Narang Journal: Curr Oncol Date: 2022-01-11 Impact factor: 3.677